HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) CME: Take the course for this article: Volume 62, Number 7, April 13, 2004 Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pons, R. Articles by De Vivo, D. C. Search for Related Content PubMed PubMed Citation Articles by Pons, R. Articles by De Vivo, D. C. Related Collections Metabolic disease (inherited) All Pediatric Developmental disorders Autonomic diseases All Clinical trials

Aromatic L-amino acid decarboxylase deficiency

Clinical features, treatment, and prognosis

From the Departments of Neurology and Pediatrics (Drs. Pons, Ford, Chiriboga, Hinton, and De Vivo), College of Physicians and Surgeons of Columbia University, New York, NY; Biochemistry Endocrinology and Metabolism Unit (Dr. Clayton), Institute of Child Health at Great Ormond Street Hospital, University College London, UK; Institute of Metabolic Disease (Drs. Hyland and Sharma), Baylor University Medical Center, Dallas, TX; and Universitat Autonoma de Barcelona (Dr. Pons), Spain.

Address correspondence and reprint requests to Dr. Darryl C. De Vivo, Neurological Institute, 710 West 168^th Street, New York, NY 10032; e-mail: dcd1{at}columbia.edu

Background: Deficiency of aromatic L-amino acid decarboxylase (AADC) is associated with severe developmental delay, oculogyric crises (OGC), and autonomic dysfunction. Treatment with dopamine agonists and MAO inhibitors is beneficial, yet long-term prognosis is unclear.

Objective: To delineate the clinical and molecular spectrum of AADC deficiency, its management, and long-term follow-up.

Results: The authors present six patients with AADC deficiency and review seven cases from the literature. All patients showed reduced catecholamine metabolites and elevation of 3-O-methyldopa in CSF. Residual plasma AADC activity ranged from undetectable to 8% of normal. Mutational spectrum was heterogeneous. All patients presented with hypotonia, hypokinesia, OGC, and signs of autonomic dysfunction since early life. Diurnal fluctuation or improvement of symptoms after sleep were noted in half of the patients. Treatment response was variable. Two groups of patients were detected: Group I (five males) responded to treatment and made developmental progress. Group II (one male, five females) responded poorly to treatment, and often developed drug-induced dyskinesias.

Conclusions: The molecular and clinical spectrum of AADC deficiency is heterogeneous. Two groups, one with predominant male sex and favorable response to treatment, and the other with predominant female sex and poor response to treatment, can be discerned.

Received June 17, 2003. Accepted in final form November 24, 2003.

This article has been cited by other articles:

				N. Watemberg, T. Lerman-Sagie, and U. Kramer Diagnostic Yield of Electroencephalograms in Infants and Young Children With Frequent Paroxysmal Eye Movements J Child Neurol, June 1, 2008; 23(6): 620 - 623. [Abstract] [PDF]

				K. Hyland Inherited Disorders Affecting Dopamine and Serotonin: Critical Neurotransmitters Derived from Aromatic Amino Acids J. Nutr., June 1, 2007; 137(6): 1568S - 1572S. [Abstract] [Full Text] [PDF]

				P. L. Pearl, J. L. Taylor, S. Trzcinski, and A. Sokohl The Pediatric Neurotransmitter Disorders J Child Neurol, May 1, 2007; 22(5): 606 - 616. [Abstract] [PDF]

				D. H. Berkowitz and A. Ganesh Combined General and Regional Anesthetic in a Child with Aromatic l-Amino Acid Decarboxylase Deficiency Anesth. Analg., December 1, 2006; 103(6): 1630 - 1631. [Full Text] [PDF]

				A. Collins and J. Jankovic Botulinum toxin injection for congenital muscular torticollis presenting in children and adults. Neurology, September 26, 2006; 67(6): 1083 - 1085. [Abstract] [Full Text] [PDF]

				P. B. Mills, R. A.H. Surtees, M. P. Champion, C. E. Beesley, N. Dalton, P. J. Scambler, S. J.R. Heales, A. Briddon, I. Scheimberg, G. F. Hoffmann, et al. Neonatal epileptic encephalopathy caused by mutations in the PNPO gene encoding pyridox(am)ine 5'-phosphate oxidase Hum. Mol. Genet., April 15, 2005; 14(8): 1077 - 1086. [Abstract] [Full Text] [PDF]